In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Abbott India has informed that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Anushree Kunhambu - Associate Director - New Product Introduction and Therapy Area Strategy effective August 1, 2025. She will be part of the Senior Management team of the Company. The additional details required under the SEBI Listing Regulations read with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015, is enclosed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
